HOME >> BIOLOGY >> NEWS
Wine, music and schizophrenia genes

NEW BRUNSWICK/PISCATAWAY, N.J. A California wine country music festival will aid a Rutgers scientist's research into schizophrenia, its causes and cures. Schizophrenia is a chronic brain disease that affects more than 2 million Americans and as many as 51 million people worldwide.

Dr. Linda Brzustowicz, an associate professor of genetics at Rutgers, The State University of New Jersey, a board certified psychiatrist and an associate professor of psychiatry at the University of Medicine and Dentistry of New Jersey (UMDNJ), was selected from more than 35 highly qualified applications for the inaugural Staglin Family Music Festival NARSAD Schizophrenia Research Award.

The Staglin Family, through the National Alliance for Research on Schizophrenia and Depression (NARSAD), the world's largest nongovernmental funding source for mental health research, established the $250,000 award to be made each year to a "rising star" scientist. It will be supported by funds raised by the Music Festival for Mental Health, an annual event at the Staglin Family Vineyard in the Napa Valley that offers music, fine wines and gourmet dining.

Founded in 1995 by Shari and Garen Staglin, the music festival has raised more than $25 million, with 100 percent funneled directly to research. "Our mission, through this festival, is to fund cutting-edge research to find the causes and cures for schizophrenia and other mental illnesses," Shari Staglin said. "We established this new award," added Garen Staglin, "to stimulate potential young scientists to enter the field of schizophrenia research." Despite the increased awareness brought about by the motion picture portrayal of Nobel Laureate John Nash's schizophrenia in "A Beautiful Mind," the conduct of research on this disease is still facing serious challenges in financial support.

"This award is particularly welcome because it comes at a time when federal funding in this area is shrinking, and we are not done u
'"/>

Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-932-7084 x652
Rutgers, the State University of New Jersey
24-Mar-2005


Page: 1 2 3

Related biology news :

1. Neurosciences and music meet in Montreal
2. Art and music for the birds
3. Pendulum love, science class gender gaps, musical mind mirrors, and unparticle physics
4. Essential tones of music rooted in human speech
5. UCLA molecular biologists convert protein sequences into classical music
6. Music genes and musical geniuses
7. The musician in the mirror
8. For crickets, parasitic flies can stop the music
9. The Strangest Song -- The story of the link between a rare genetic disorder and musical talent
10. Loud music worsens effects of taking ecstasy
11. NJIT professor explains bird songs with science, poetry, music

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Wine music and schizophrenia genes

(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: